COMMUNIQUÉS West-GlobeNewswire

Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion
09/10/2025
Shareholders to Receive $54 Per Share in Cash and CVR of $6 Per Share Advances Akero’s Mission of Bringing Novel Therapies to Patients with High Unmet Medical Needs SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE [...]
Human Appeal's Pot of Gold Film to Air on EarthX Channel on October 18
09/10/2025
BayView Entertainment to Bring Groundbreaking Documentary to Streaming and Broadcast Audiences MISSION VIEJO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pot of Gold , a powerful independent documentary set in the [...]
Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio
09/10/2025
Acquisition adds potential first- and best-in-class asset, enhancing Novo Nordisk’s portfolio for treatment of MASH, one of the most prevalent obesity related comorbidities Akero Therapeutics’s FGF21 analogue [...]
Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial
09/10/2025
STAFFORD, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
09/10/2025
VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the [...]
Italfarmaco Appoints Francesco Di Marco as Chief Executive Officer
09/10/2025
MILAN, Italy, October 09, 2025 – Italfarmaco S.p.A. today announced that Dr. Francesco Di Marco has been appointed as Chief Executive Officer (CEO), effective January 1, 2026. Dr. Di Marco brings over 25 years of [...]
Tensive publishes positive long-term clinical follow-up data in Breast Cancer on REGENERA™ / SOFTAG™ breast implant
09/10/2025
24-month Phase I follow-up data show positive outcomes are maintained High levels of investigator and patient satisfaction, excellent safety profile Ongoing registrational trial will yield top-line results before the [...]
Ariceum Therapeutics Data at the 2025 European Association of Nuclear Medicine Annual Congress Further Supports the Advancement of 225Ac-SSO110 for Extensive Stage Small Cell Lung Cancer and Merkel Cell Carcinoma
09/10/2025
Oral presentation by Dr Zan highlighted novel Phase 1/2 SANTANA-225 study design of 225Ac-SSO110 in patients with ES-SCLC or MCC 225Ac-SSO110 achieves superior pharmacokinetics with minimal re-distribution of Actinium- [...]

Pages